# Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)

Source: https://onco.cc/trials/nct07079475/  
OnCo record `nct07079475` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Sunvozertinib, Osimertinib in non-small-cell lung cancer and small-cell lung cancer, run by Dizal Pharmaceuticals, now recruiting.

## Summary

Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8) is a phase 1/2 interventional study registered as NCT07079475 by Dizal Pharmaceuticals, with 220 participants planned, started 2025-07-30 and due to reach its primary completion in 2028-06. Interventions recorded: DZD6008, Sunvozertinib, Osimertinib. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07079475
- Phase: 1/2
- Setting: A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD6008 Combined With Sunvozertinib in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations (TIAN-SHAN8)
- Sponsor: Dizal Pharmaceuticals
- Enrolled: 220

## Sources

- ClinicalTrials.gov NCT07079475: https://clinicaltrials.gov/study/NCT07079475

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Osimertinib](https://onco.cc/drugs/osimertinib/), [Sunvozertinib](https://onco.cc/drugs/sunvozertinib/)
- companies: [Dizal Pharmaceutical](https://onco.cc/companies/dizal/)

---
JSON: https://onco.cc/api/v1/entities/nct07079475.json